AstraZeneca said results from a clinical trial showed its lung cancer drug reduced the risk of death by more than a fifth in patients with previously-untreated extensive-stage small cell lung cancer.

Imfinzi in combination with four cycles of standard-of-care (SoC) chemotherapy - etoposide with either cisplatin or carboplatin - had demonstrated a 'statistically-significant and clinically-meaningful improvement in OS (overall survival) versus SoC consisting of up to six cycles of chemotherapy and optional prophylactic cranial irradiation (PCI),' the company said.

The risk of death was reduced by 27%, with median OS of 13.0 months for Imfinzi plus chemotherapy versus10.3 months for SoC, the company added.

'Results showed a prolonged OS benefit with an estimated 33.9% of patients alive at 18 months following treatment with Imfinzi plus chemotherapy versus 24.7% of patients following SoC, the company said.


At 8:56am: (LON:AZN) AstraZeneca PLC share price was +23p at 7278p